PharmaResearch announced on the 6th that it has completed domestic patent registration for the “nucleic acid-mediated therapeutic delivery composition,” the core technology of its next-generation nano anticancer drug “PRD-101.”

This patent concerns a DOT-based drug delivery composition, PharmaResearch’s proprietary technology, and is characterized by implementing doxorubicin, an anticancer component, in the form of DNA-based nanoparticles. The company stated that the technology is designed so that DNA precisely processed through DOT technology is combined and structured with the drug, thereby controlling the drug’s delivery mechanism in the body.

PharmaResearch explained that by implementing a composition that forms uniform nanoparticles, it has presented the potential to reduce the toxicity and adverse reaction burden raised with existing anticancer drugs and to improve the efficiency and safety of in vivo drug delivery.

The technology was also granted a patent in Japan last year, and with this domestic patent registration, the company has secured rights in both countries. PharmaResearch plans to sequentially pursue patent procedures in major markets such as Australia, the United States, and Europe to strengthen its global intellectual property portfolio.

A PharmaResearch official said, “PRD-101 is differentiated in that it has been designed with a delivery structure that can compensate for the limitations of existing formulations,” adding, “This patent is significant as it demonstrates an expansion of the application scope of DOT, PharmaResearch’s core DNA technology that has been accumulated for more than a decade.”

Meanwhile, PharmaResearch recently obtained Phase 1 clinical trial Investigational New Drug (IND) approval for PRD-101 from the U.S. Food and Drug Administration (FDA). Based on the secured intellectual property rights and the progress of U.S. clinical trials, the company plans to gradually verify its safety and applicability.

Popular News